X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
STX-001 is a novel programmable self-replicating mRNA encapsulated in lipid nanoparticles (LNPs), being evaluated for THE treatment of advanced solid tumors.
Lead Product(s): STX-001,Pembrolizumab
Therapeutic Area: Oncology Product Name: STX-001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2024
Details:
The funding will be used to advance Strand’s first drug candidate, a programmable mRNA therapy for solid tumor immuno-oncology into Phase 1 clinical trials next year.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: FPV
Deal Size: $97.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing November 28, 2022
Details:
Strand will use the funds from the contract to develop an in situ, off-the-shelf cell therapy based on the company’s proprietary self-replication, programmable mRNA platform to illicit a targeted CD19 CAR-T response.
Lead Product(s): mRNA-based CAR-T Immunotherapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding November 09, 2021
Details:
Strand Therapeutics awarded two Phase I Small Business Innovation Research (SBIR) grants from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to develop mRNA-based therapeutics for melanoma and triple negative breast cancer (TNBC).
Lead Product(s): mRNA-based Therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Funding August 04, 2021
Details:
Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 clinical trials.
Lead Product(s): mRNA-based Therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Redmile Group
Deal Size: $52.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 23, 2021
Details:
BeiGene gets option to license to develop and commercialize in Asia, Australia, and New Zealand up to two immuno-oncology programs using Strand’s intratumoral or systemic delivery mechanism, to deliver a tumor microenvironment-modifying mRNA directly to the tumor site.
Lead Product(s): mRNA-based therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: BeiGene
Deal Size: $320.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
